Tumor angiogenesis as a therapeutic target

Drug Discovery Today

Volumn 6, Issue 19, 2001, Pages 1005-1024

  Matter, Alex ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CGS 27023A; CH 4815; CP 564959; D 1927; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GW 2286; MARIMASTAT; METALLOPROTEINASE INHIBITOR; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; NSC 683551; OPB 3206; PD 173074; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; SOLIMASTAT; SQUALAMINE; TANOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; CANCER; HUMAN; NONHUMAN; REVIEW; TUMOR;

EID: 0035479234     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01939-0     Document Type: Review

References (208)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Seminars in medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis
3. Integrins and cancer
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Molecular angiogenesis
6. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
7. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
8. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
9. Signaling angiogenesis and lymphangiogenesis
10. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family
11. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
12. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
13. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
14. Signaling vascular morphogenesis and maintenance
15. Vascular-specific growth factors and blood vessel formation
16. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
17. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border
18. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
19. Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2
20. Oligomeric structure of the human EphB2 receptor SAM domain
21. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
22. Matrix metalloproteinase inhibitors
23. Recent insights into the role of integrins in cancer metastasis
24. Requirement of vascular integrin for angiogenesis
25. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
26. v integrins
27. The role of adhesion in metastasis: potential mechanisms and modulation of integrin activity
28. Current status of antiangiogenic factors
29. The rationale and future potential of angiogenesis inhibitors in neoplasia
30. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors
31. Tumor angiogenesis - new drugs on the lock
32. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
33. Inhibitors of tyrosine kinase
34. Current progress towards the development of tyrosine kinase inhibitors as anticancer agents
35. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
36. Small molecule inhibitors of receptor tyrosine kinases
37. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
38. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
39. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis
40. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues
41. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
42. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
43. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
44. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy
45. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
46. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
47. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
48. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
49. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
50. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
51. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase
52. Matrix metalloproteinase inhibitors
53. Recent advances in inhibitors of matrix metalloproteinases for cancer therapy
54. Preclinical and clinical studies of MMP inhibitors in cancer
55. Batimastat and Marimastat in cancer: summary of early clinical trials
56. Discovery of CGS27023A, a non-peptidic, potent and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits
57. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies
58. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations
59. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
60. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
61. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth
62. Cytostatic inhibition of endothelial cell growth by the angiogenesis TNP-470 (AGM-1470)
63. Anti-angiogenic therapies in cancer clinical trials
64. Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470
65. The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis
66. Effects of AGM-1470 and pentosan polysulfate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells
67. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
68. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
69. The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary-tumors
70. Potentiation of cytotoxic cancer therapy by TNP-470 alone and with other anti-angiogenic agents
71. Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470
72. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin
73. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells
74. Thalidomide is an inhibitor of angiogenesis
75. Thalidomide and analogs
76. Effect of thalidomide on tumor necrosis factor production and antitumor activity induced by 5,6-dimethylxanthenone-4-acetic acid
77. Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies
78. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
79. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
80. Squalamine: an aminosterol antibiotic from the shark
81. Squalamine: a new angiostatic steroid
82. + exchanger isoform NHE3
83. Potentiation of platinum effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects of tumor neovascularization
84. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth
85. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
86. Angiostatin protein and other plasminogen fragments
87. Suppression of tumor growth with recombinant murine angiostatin
88. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer
89. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
90. Angiostatin and Endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth
91. Angiostatin and Endostatin: endogenous inhibitors of tumor growth
92. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
93. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
94. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis
95. Treatment of haemangioendotheliomas with alpha interferon
96. Treatment of pulmonary hemangiomatosis with recombinant interferon α-2a
97. Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications?
98. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis
99. Antiangiogenic tumour therapy: will it work?
100. Design and structure-activity relationship of a new class of potent VEGF receptor-tyrosine kinase inhibitors
101. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
102. Chiroscience/BMS MMP inhibitor progress
103. Plasma levels of COL-3 in rats and monkeys
104. Mercaptoacyl matrix metalloproteinase inhibitors: the effect of substitution at the mercaptoacyl moiety
105. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
106. A novel synthetic matrix metalloproteinase inhibitor OPB-3206: inhibition of tumor growth metastasis, and angiogenesis
107. Accidental' antiangiogenic drugs: anti-oncogene directed signal transduction inhibitors
108. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing
109. Acitretin decreases tumor cell-induced angiogenesis
110. Transduction of retinoic acid and gamma-interferon signal for intercellular adhesion molecule-1 expression on human tumor cell lines: evidence for the late-acting involvement of protein kinase C inactivation
111. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP)
112. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells
113. Retinoic acid and interferon-α act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma
114. Potent, selective, orally active 3-Oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists
115. v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors
116. v integrins during angiogenesis: insights into potential mechanisms of action and clinical development
117. Zoledronate: the preclinical pharmacology
118. A dose-finding study of zoledronate in hypercalcemic cancer patients
119. Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide
120. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers
121. Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants
122. Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide
123. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent
124. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
125. Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole
126. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations
127. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor
128. Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity
129. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator
130. Thymidine phosphorylase is angiogenic and promotes tumour growth
131. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer
132. Suramin and prostate cancer: where do we go from here?
133. Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas
134. Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate
135. Effects of AGM-1470 and pentosan polysulfate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells
136. Pentosan polysulfate: A polysaccharide that inhibits angiogenesis by binding growth factors
137. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors
138. Novel non-cross resistant diaminoanthraquinones as potential chemotherapeutic agents
139. A diaminoanthraquinone inhibitor of angiogenesis
140. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
141. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth
142. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
143. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression
144. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain
145. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro
146. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo
147. Tecogalan sodium inhibits corneal neovascularization induced by basic fibroblast growth factor
148. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium
149. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121
150. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
151. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
152. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans
153. 3 blocks human breast cancer growth and angiogenesis in human skin
154. 3
155. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
156. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinases insert domain-containing receptor antibody
157. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor
158. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
159. Treatment of haemangioendotheliomas with alpha interferon
160. Treatment of pulmonary hemangiomatosis with recombinant interferon α-2a
161. Interferon α-2a therapy for life-threatening hemangiomas of infancy
162. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma
163. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane
164. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide; a potential treatment for ocular neovascularization
165. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995)
166. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
167. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
168. Troponin I is present in human cartilage and inhibits angiogenesis
169. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
170. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
171. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
172. Enhancement of the anti-tumor effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
173. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
174. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
175. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis
176. v-Integrins as receptors for tumor targeting by circulating ligands
177. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
178. Chemotherapy targeted to tumor vasculature
179. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
180. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate
181. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA
182. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src
183. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer
184. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin
185. Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein
186. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin
187. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector
188. Considerations and challenges for the achievement of targeted gene delivery
189. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins
190. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
191. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
192. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
193. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
194. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
195. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
196. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
197. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest